



KnowledgeEdge™

HTA Impact on Global Access

Global Market Access HTA Decision Making Landscape

Executive Summary

SEPTEMBER 2017



HealthStrategiesGroup

Global Access Insights: A Partnership with Visionary Ventures

Clients Receive



On-call access to our research leaders for your inquiries



Onsite presentations and working sessions



Access to our website, customized for your organization



Multiple syndicated research studies delivered throughout the year in print and electronic format



Client exclusive webinar to access research on-demand

**Call us today to schedule your on-site briefing of the enclosed research.
609.397.5282**

Industry experts, here for you, sharing insights to help move your business ahead.

Your input is valuable.

We'd like your feedback and comments. Please visit www.HealthStrategies.com.

Thanks for letting us know how we're doing so we can better meet your specific business challenges.

2017 Syndicated Services

Brand Access and Distribution Insights

- DecisionEdge™ Market Access Brand Value Proposition
- DecisionEdge™ Patient Access Journey
- KnowledgeEdge™ Brand Access Marketplace Dynamics
- KnowledgeEdge™ Impact of Risk-based Contracting on Market Access
- Oncology Pathways Insight and Evolution
- Specialty Pharmacy Manager Navigator

Company and Account Team Performance and Benchmarking

- PerformanceEdge™ Market Access Customer Relationships—MCO
- PerformanceEdge™ Market Access Customer Relationships—IDN

Organized Provider Trends and Profiles

- Accountable Care Organizations
- Health System Profiles
- Institutional Channel Assessment

Payer Trends and Profiles

- KnowledgeEdge™ Assessment of Healthcare Policy Decisions
- Managed Medicare Rx
- Medicaid Rx Payers
- National Account Full Profiles
- Payer Landscape for Specialty Pharmaceuticals
- Pharmacy Benefit Managers
- Regional and Blues Health Plan Profiles
- Strategic Accounts

2017 Custom Market Research

Expand the reach and impact of your purchased Syndicated Research through our Custom Access Insights which brings an advanced set of a global market access capabilities, frameworks, and methods, plus our robust panel, to answer your specific market access questions across the product lifecycle, from clinical development to loss of exclusivity.

Research Overview

Global Market Access HTA Decision Making Landscape

This research is the second publication from the HTA Impact on Global Access (HTAI) service for 2017.

Key Topics

- **HTA agency assessment and interpretation of submitted evidence**
 - Drivers that shape positive and negative coverage recommendations
- **Rationale and patterns behind HTA coverage recommendations**
 - Real-world category-specific case studies
- **Implications and key takeaways for biopharmaceutical companies**

Methodology

- Health Strategies Group's research includes access to data held by LSE, comprising a uniform, homogeneous sample data set of HTA recommendations for 101 drug-indication pairs.
 - Data spans across Australia, Canada, England, France, Germany, Scotland, and Sweden from 2012 to 2017.
 - In Germany, both IQWiG recommendations and G-BA decisions were investigated.
 - In Canada, CADTH/pCODR decisions at the Federal level and INESSS (Quebec) recommendations at the provincial level were investigated.
 - This research covers over 900 data points for the following therapeutic drug categories: anticoagulants, asthma/COPD, autoimmune, cardiovascular, diabetes, hepatitis C, HIV, multiple sclerosis, oncology, and orphan/rare diseases.
- Our research also includes 26 online surveys with current and former HTA agency senior staff members and other experts.

Source: Health Strategies Group, HTA Impact on Global Access, September 2017.

Table of Contents

Introduction	5
Executive Summary	7
HTA Agency Assessment and Interpretation of Submitted Evidence	17
Rationale and Patterns Behind HTA Recommendations	38
Therapeutic Class Case Study: Prostate Cancer	45
CNS Case Study: Aubagio®	49
Oncology Case Study: Zykadia®	52
Orphan Drug Case Study: Soliris®	55
Biopharmaceutical Company Responses to Negative HTA Coverage Recommendations	59
Key Takeaways for Biopharmaceutical Companies	66
Appendix	68

Figure List

Variations in HTA Recommendations by Country	5
Variations in Positive HTA Recommendations by Therapeutic Category	7
Potential Biopharmaceutical Company Responses to Negative HTA Recommendations	12
Clustered Reasons for DNL Recommendations: Oncology	25
HTA Coverage Recommendations for Pertuzumab	32
Evidence Criteria Emphasis Differs Across Countries	40
Economic Criterion Importance Towards HTA Decision-Making	45
Similarities in Clinical Evidence by Therapeutic Category	57
Differences in Clinical Evidence Within Prostate Cancer	60
Yervoy® Case Study: Managed Entry Agreement to Remedy DNL Recommendation	62
Tafinlar® Case Study: Resubmission to Remedy DNL Recommendation	66



East Coast Office

790 Township Line Road, Suite 300
Yardley, PA 19067
v: 609.397.5282 f: 609.397.5283

West Coast Office

20 Pacifica, Suite 320
Irvine, CA 92618
v: 949.242.1035 f: 949.587.9260

www.HealthStrategies.com

This Report is licensed only to the original party licensed by Health Strategies Group, Inc. (respectively the "Licensee" and "Health Strategies Group") and is subject to a binding license agreement between Licensee and Health Strategies Group. Health Strategies Group continues to retain title to and ownership of this Report. All copies and portions of this Report, in any form, belong to Health Strategies Group, which retains all rights not expressly granted. Licensee is entitled to use this Report solely for its own internal business purposes and is prohibited from modifying, translating, or otherwise creating derivative works based on this Report. Licensee is further prohibited from licensing, selling, leasing, distributing, lending or otherwise transferring this Report to any third party. Licensee may not make any copies of Health Strategies Group's Reports except for internal distribution purposes as described and agreed to in the license agreement provided that all such copies are reproduced with and incorporate all of Health Strategies Group's protective notices, including this and all copyright notices. Nothing in this Report and/or any license agreement applicable thereto constitute a waiver of Health Strategies Group's rights under United States copyright law or any other law.

This information has been obtained from sources which Health Strategies Group believes to be reliable but we do not guarantee the accuracy or completeness of this information.